<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ayu</journal-id><journal-id journal-id-type="iso-abbrev">Ayu</journal-id><journal-id journal-id-type="publisher-id">AYU</journal-id><journal-title-group><journal-title>Ayu</journal-title></journal-title-group><issn pub-type="ppub">0974-8520</issn><issn pub-type="epub">0976-9382</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24696570</article-id><article-id pub-id-type="pmc">3968694</article-id><article-id pub-id-type="publisher-id">AYU-34-346</article-id><article-id pub-id-type="doi">10.4103/0974-8520.127692</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Effect of <italic>Sameera Pannaga Rasa</italic> (arsenomercurial formulation) in the management of <italic>Tamaka Shwasa</italic> (bronchial asthma) - Randomized double blind clinical study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mashru</surname><given-names>Mayur</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Galib</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Shukla</surname><given-names>Vinay J.</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Ravishankar</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Prajapati</surname><given-names>Pradeep Kumar</given-names></name><xref ref-type="aff" rid="aff5">4</xref></contrib></contrib-group><aff id="aff1">Superintendent, Government Ayurved Hospital Popatpura, Godhra, India</aff><aff id="aff2"><label>1</label>Assistant Professor, Department of Rasashastra and Bhaishajya Kalpana, Institute for Post Graduate Teaching and Research in Ayurveda, Jamnagar, Gujarat, India</aff><aff id="aff3"><label>2</label>Head, Pharmaceutical Chemistry Laboratory, Institute for Post Graduate Teaching and Research in Ayurveda, Jamnagar, Gujarat, India</aff><aff id="aff4"><label>3</label>Director, Research and Development, S.D.M. Research Center for Ayurveda and Allied Sciences, Udupi, Karnataka, India</aff><aff id="aff5"><label>4</label>Professor and Head, Department of Rasashastra and Bhaishajya Kalpana Including Drug Research, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Mayur Mashru, Govt. Ayurved Hospital, Popatpura, Godhra, Panchmahal, Gujarat, India. E-mail: <email xlink:href="ayubeat.mayur@gmail.com">ayubeat.mayur@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2013</year></pub-date><volume>34</volume><issue>4</issue><fpage>346</fpage><lpage>351</lpage><permissions><copyright-statement>Copyright: &#x000a9; AYU (An International Quarterly Journal of Research in Ayurveda)</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Asthma represents a profound world-wide public health problem. The most effective anti-asthmatic drugs currently available include &#x003b2;2-agonists and glucocorticoids which can controls asthma in about 90-95% of patients. In Ayurveda, this miserable condition is comparable with <italic>Tamaka Shwasa</italic> type of <italic>Shwasa Roga</italic>. In the present study, 52 patients were treated with <italic>Sameera Pannaga Rasa</italic> at a dose of 30 mg twice a day for 4 weeks along with <italic>Nagavallidala</italic> (leaf of <italic>Piper betel</italic> Linn.) The results were assessed in terms of clinical recovery, symptomatic relief, pulmonary function improvement and on subjective and objective parameters. A significant improvement in subjective parameters, control on asthma, recurrence of asthma, increase in peak expiratory flow rate, considerable decrease in total and absolute, acute eosinophil count and erythrocyte sedimentation rate were observed. Overall marked improvement was found in 33.33%, moderate improvement in 44.44% and mild improvement in 20.00% was observed. The study reveals that <italic>Sameera Pannaga Rasa</italic> can be used as an effective drug in bronchial asthma.</p></abstract><kwd-group><kwd>Bronchial asthma</kwd><kwd>pulmonary function</kwd><kwd><italic>Sameera Pannaga Rasa</italic></kwd><kwd><italic>Shwasa</italic></kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><p>Asthma represents a profound world-wide public health problem. The past decade has witnessed phenomenal increases in the incidences of asthma, asthma-related deaths and Glucocorticoids are the drugs frequently used (about 95%) in the treatment of bronchial asthma.[<xref rid="ref1" ref-type="bibr">1</xref>] Currently glucocorticoid dependent asthma presents a great clinical burden and reducing the side-effects of glucocorticoids using novel steroid-sparing agents is needed.[<xref rid="ref2" ref-type="bibr">2</xref>] However, the future therapies will need to focus on the 5-10% patients who do not respond well to these treatments and who account for approximately 50% of the health-care costs of asthma.[<xref rid="ref3" ref-type="bibr">3</xref>] The surveys in adults show high prevalence of asthma symptoms and reduced lung functions particularly in lower socio-economic groups of the sufferers.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] Asthma causes recurring episodes of wheezing, breathlessness, chest tightness and coughing, particularly at night or in the early morning. Common risk factors for asthma include exposure to allergens (such as those for house dust mites, animal with fur, cockroaches, pollens and mold),[<xref rid="ref6" ref-type="bibr">6</xref>] occupational irritants,[<xref rid="ref7" ref-type="bibr">7</xref>] tobacco smoke,[<xref rid="ref8" ref-type="bibr">8</xref>] respiratory (viral) infections,[<xref rid="ref9" ref-type="bibr">9</xref>] chemical irritants,[<xref rid="ref7" ref-type="bibr">7</xref>] food allergies such as milk, peanuts and eggs[<xref rid="ref10" ref-type="bibr">10</xref>] and psychological stress.[<xref rid="ref11" ref-type="bibr">11</xref>] When airways are exposed to any of these risk factors; broncho-constriction will get manifested leading to inflammation. The airflow becomes limited and the patient suffers with the symptoms of asthma. The disease is comparable with <italic>Tamaka Shwasa</italic> type of <italic>Shwasa Roga</italic> in Ayurveda.[<xref rid="ref12" ref-type="bibr">12</xref>] Ayurveda prefers a number of formulations to treat <italic>Tamaka Shwasa</italic>, which include few metallic preparation. <italic>Sameera Panaga Rasa</italic> (SPR) is an among such preperation, which is indicated in <italic>Tamaka Shwasa</italic>.[<xref rid="ref13" ref-type="bibr">13</xref>]</p><p>SPR, an arsenal mercurial formulation is mentioned in <italic>Rasa Chandanshu</italic> in which <italic>Manahshila</italic> is not a component and later on it has been added by Ayurveda Aaushadhi Guna Dharma Shashtra. This later version has been accepted by Ayurvedic Formulary of India but, justification regarding the addition of <italic>Manahshila</italic> has not been provided. In addition to this; there is controversy regarding the final product, i.e., whether to collect <italic>Talastha</italic> or <italic>Ubhayastha (Galastha + Talastha)</italic>. Considering this, it is planned to prepare SPR with and without <italic>Manahashila</italic> and collect <italic>Talastha</italic> and <italic>Ubhayastha</italic> one and compare their respective clinical efficacies in <italic>Tamaka Shwasa</italic>.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><sec id="sec2-1"><title>Selection of patients</title><p>For this study, 52 patients of bronchial asthma were registered from the out-patient department and inpatient department of Rasashastra and Bhaishajya Kalpana including Drug Research, IPGT and RA, Gujarat Ayurved University, Jamnagar. Of all, seven patients were dropped out and 45 completed the prescribed course of treatment. No direct or indirect drug related reason for discontinue of patient was noticed. All the patients registered in the study were informed about the nature of treatment. The study was started after obtaining approval from the Institutional Ethics Committee.</p></sec><sec id="sec2-2"><title>Criteria for inclusion</title><p>
<list list-type="order"><list-item><p>Age between 20 to 60 years</p></list-item><list-item><p>Difficulty in breathing</p></list-item><list-item><p>Paroxysmal attacks of dyspnea</p></list-item><list-item><p>Difficulty in expectoration</p></list-item><list-item><p>Wheezing sounds</p></list-item><list-item><p>Relief in upright position.</p></list-item></list>
</p></sec><sec id="sec3-1"><title>Criteria for exclusion</title><p>
<list list-type="order"><list-item><p>Age below 20 and above 60 years</p></list-item><list-item><p>Acute asthma requiring emergency medicines</p></list-item><list-item><p>History of Bronchiectasis, Tuberculosis, Pyothorax, Anemia, Malignancy, Diabetes Mellitus, Hypertention, Hepatic or Renal disease in the recent past</p></list-item><list-item><p>Dyspnea resulting from cardiac disease</p></list-item><list-item><p><italic>Maha Shwasa</italic>, <italic>Urdhva Shwasa</italic> and <italic>Chhinna Shwasa</italic> (types of breathlessness explained in classics) which have been labeled as incurable in Ayurveda.</p></list-item></list>
</p></sec><sec id="sec2-3"><title>Posology</title><p>The trial drug (SPR) was prepared in the departmental laboratory by following standard manufacturing procedures (SMP). The formulation composition is shown in <xref ref-type="table" rid="T1">Table 1</xref>. SPR prepared without <italic>Manahshila</italic> was labeled as SPR and that prepared with <italic>Manahshila</italic> was labeled as SPRM. Groups for clinical trial were as follows:</p><p>
<list list-type="bullet"><list-item><p>Group A: Treated with SPR prepared without <italic>Manahshila - Talastha</italic> (SPRT)</p></list-item><list-item><p>Group B: Treated with SPR prepared without <italic>Manahshila - Ubhayastha (Galastha + Talastha)</italic> (SPRU)</p></list-item><list-item><p>Group C: Treated with SPR prepared with <italic>Manahshila - Talastha</italic> (SPRMT)</p></list-item><list-item><p>Group D: Treated with SPR prepared with <italic>Manahshila - Ubhayastha (Galastha + Talastha)</italic> (SPRMU).</p></list-item></list>
</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Formulation composition of <italic>Sameera Pannaga Rasa</italic></p></caption><graphic xlink:href="AYU-34-346-g001"/></table-wrap><p>A capsule of 250 mg (containing 30 mg SPR + 220 mg starch powder) was administered twice a day for 28 days along with juice of <italic>Nagavallidala</italic> (leaf of <italic>Piper betel</italic> Linn.) as <italic>Sahapana</italic> (adjuvant). Follow-up was done after 2 weeks. Patients were advised not to get exposed to the susceptible triggering or aggravating factors narrated in Ayurveda as well as in modern texts.</p></sec><sec id="sec2-4"><title>Laboratory investigations</title><p>Routine hematological, biochemical investigations, and peak expiratory flow rate (PEFR) were done before and after the treatment. Sputum examination and chest X-ray were carried out to exclude pulmonary tuberculosis and other pulmonary diseases.</p></sec><sec id="sec2-5"><title>Assessment criteria</title><p>Registered patients were advised to visit the OPD at regular intervals of a week. Subjective and objective parameters were recorded in terms of improvement in pulmonary functions and other investigations. Overall assessment of the treatment was made on the basis of the results of the investigations as well as the symptomatic relief.</p></sec><sec id="sec2-6"><title>Results and interpretation</title><p>Overall effect of therapy on each scale was calculated with reference to percentage improvement in all symptoms, the relief was assessed on the below criteria:</p><p>
<list list-type="order"><list-item><p>&#x0003c;25% - Poor response/unchanged</p></list-item><list-item><p>26-50% - Mild improvement</p></list-item><list-item><p>51-75% - Moderate improvement</p></list-item><list-item><p>76-99% - Marked improvement</p></list-item><list-item><p>100% - Complete remission.</p></list-item></list>
</p></sec><sec id="sec2-7"><title>Statistical analysis</title><p>Wilcoxon signed rank test was applied to evaluate the overall effect of therapy. Paired <italic>t</italic>-test was applied to evaluate the effect on hematological, biochemical investigation and PEFR.</p></sec></sec><sec id="sec1-3"><title>Observations and Results</title><p>Four patients (33.33%) of SPRT group, four patients (36.36%) of SPRU group, two patients (20.00%) of SPRMT group and five patients of (41.67%) group SPRMU showed marked improvement. Five patients (41.67%) of SPRT group, five patients (45.45%) of SPRU group, three patients (30.00%) of SPRMT group and seven patients of (58.33%) group SPRMU showed moderate improvement and three patients (25.00%) of SPRT group, two patients (18.18%) of SPRU group and four patients (40.00%) of SPRMT group showed mild improvement. In SPRMT group, one patient (10.00%) did not respond to the treatment. Overall results have been tabulated in <xref ref-type="table" rid="T2">Table 2</xref>. All the groups have been found to be statistically highly significant providing in relief [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Overall effect of the therapy (In percentage)</p></caption><graphic xlink:href="AYU-34-346-g002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Effect of drugs on overall effect of therapy: (Applied Wilcoxon rank test)</p></caption><graphic xlink:href="AYU-34-346-g003"/></table-wrap><p>The reduction in eosinophils count, erythrocyte sedimentation rate (ESR) and total leucocyte count are found to be insignificant [Tables <xref ref-type="table" rid="T4">4</xref>&#x02013;<xref ref-type="table" rid="T7">7</xref>]. It was found in the study that, the duration, paroxysm, wheezing, chest tightness, nocturnal symptoms and dosage of allopathic emergency medicines were drastically reduced.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Hematological results of SPRT (applied paired <italic>t</italic> test)</p></caption><graphic xlink:href="AYU-34-346-g004"/></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Hematological results of SPRT (applied paired <italic>t</italic> test)</p></caption><graphic xlink:href="AYU-34-346-g005"/></table-wrap><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Hematological results of SPRMT (applied paired <italic>t</italic> test)</p></caption><graphic xlink:href="AYU-34-346-g006"/></table-wrap><table-wrap id="T7" position="float"><label>Table 7</label><caption><p>Hematological results of SPRMU (applied paired <italic>t</italic> test)</p></caption><graphic xlink:href="AYU-34-346-g007"/></table-wrap><p>Interestingly, most of the patients in their follow-up period did not require the need of any emergency medication, particularly in SPRMU group followed by SPRT and SPRU group [<xref ref-type="table" rid="T8">Table 8</xref>]. Level of asthma control was higher in SPRMT group (50.00%) and in SPRU group (45.55%) [<xref ref-type="table" rid="T9">Table 9</xref>].</p><table-wrap id="T8" position="float"><label>Table 8</label><caption><p>Effect of drugs on withdrawal of emergency drugs (applied Wilcoxon rank test)</p></caption><graphic xlink:href="AYU-34-346-g008"/></table-wrap><table-wrap id="T9" position="float"><label>Table 9</label><caption><p>Level of asthma control before treatment and after treatment</p></caption><graphic xlink:href="AYU-34-346-g009"/></table-wrap><p>As per ACT score, it was found that by SPRMU and SPRT groups provided statistically significant results in control of asthma [<xref ref-type="table" rid="T10">Table 10</xref>]. No recurrence of attacks was observed during follow-up period in SPRMU group [<xref ref-type="table" rid="T11">Table 11</xref>].</p><table-wrap id="T10" position="float"><label>Table 10</label><caption><p>Effect of SPRT on asthma control&#x02020; (applied &#x003c7;<sup>2</sup>)</p></caption><graphic xlink:href="AYU-34-346-g010"/></table-wrap><table-wrap id="T11" position="float"><label>Table 11</label><caption><p>Recurrence asthma in follow-up period (in percentage)</p></caption><graphic xlink:href="AYU-34-346-g011"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>Survey of available literature points out that, vitiation of <italic>Vata</italic>, <italic>Kapha Dosha</italic> along with <italic>Prana</italic>, <italic>Udaka</italic> and <italic>Anna Vaha Srotas</italic> and <italic>Rasa Dhatu</italic> are the responsible factors in the manifestation of <italic>Tamaka Shwasa</italic>. The disease <italic>Shwasa</italic> has its root in the <italic>Pitta Sthana</italic> endorsed by <italic>Amashayodbhavaja Vikara</italic>.[<xref rid="ref14" ref-type="bibr">14</xref>]</p><p>Considering the aggravated <italic>Vata and Kapha, Acharyas</italic> have advised the use of <italic>Vata kaphaghna</italic>, <italic>Ushna, Vatanulomaka</italic> drugs as first line of treatment in <italic>Shwasa</italic>. However, adoption of certain specification is always required for the breakdown of the three pathways of <italic>Samprapti</italic>. Furthermore, drugs exhibiting quick control over vitiated <italic>Vata</italic> and <italic>Kapha</italic> are required during <italic>Vegavastha</italic>, while exerting action on <italic>Agni</italic> or <italic>Pittasthana</italic> along with <italic>Vatakaphaghnata</italic>. Hence, logically, the drug administered in the treatment of <italic>Shwasa</italic>, should be able to overcome <italic>Vata</italic> and <italic>Kapha</italic> for immediate and symptomatic relief but should also pacify the <italic>Pitta</italic> for relief. Vagbhata emphasizes that, a drug acts by its <italic>Rasa</italic>, <italic>Vipaka</italic>, <italic>Virya</italic>, <italic>Guna</italic> and <italic>Prabhava</italic>. Normally, the effect of <italic>Rasa</italic> is less than that of <italic>Vipaka</italic>. Effect of <italic>Vipaka</italic> is lesser than that of Virya, which further is lesser than <italic>Prabhava</italic>, provided all are present in equal proportions. The overall pharmacodynamics of SPR is <italic>Katu Rasa, Ushna Guna, Ushna Virya, Katu Vipaka</italic> and <italic>Kapha Vataghna</italic>.[<xref rid="ref15" ref-type="bibr">15</xref>] These dynamic actions are helpful in breaking the pathogenesis of <italic>Tamaka Shwasa</italic>. Asthma is now accepted as a T-helper type 2 lymphocyte-mediated chronic inflammatory disorder, characterized by airway eosinophilia and airway hyper responsiveness. Eosinophils appear to play a crucial role in the ongoing inflammation due to either an impaired clearance or a delayed apoptosis in the airways, where accumulation of a number of eosinophils cytotoxic proteins including major basic protein, cationic proteins and peroxidase could occur. As2o3 could alleviate the airway inflammation through promoting pulmonary eiosinophils (PE) apoptosis and lower PE infiltration. Low dose of As2o3 is proved to be effective with relative safety, it also has potential value in treating asthma.[<xref rid="ref16" ref-type="bibr">16</xref>]</p><p>In modern point of view SPR is Mercury-Arsenical (<italic>Ubhayastha</italic>) or Arsenical preparation (<italic>Talastha</italic>).</p><p>In preparation of SPR, <italic>Tulsipatra Swarasa</italic> (leaf of <italic>Oscimum sanctum</italic> Linn.) as <italic>Bhavana Dravya</italic> is advocated. Studies have been proved that leaf extract of <italic>Ocimum sanctum</italic> is effective against arsenic induced toxicity. <italic>Ocimum sanctum</italic> has significant role in protecting animals from arsenic induced oxidative stress and in the depletion of arsenic concentration.[<xref rid="ref17" ref-type="bibr">17</xref>] It has been proved that <italic>Ocimum</italic> extract can protect against mercury toxicity in mice. It significantly enhanced reduced glutathione, which is suggested that oral administration of <italic>Ocimum</italic> extract provides protection against mercury induced toxicity in Swiss albino mice.[<xref rid="ref18" ref-type="bibr">18</xref>] Thus, Oscimum may help in nullifying possible ADRs of SPR.[<xref rid="ref19" ref-type="bibr">19</xref>]</p><p>In the present study, <italic>Nagavallidala</italic> (<italic>P. betel</italic>) was taken as <italic>Sahapana</italic> for SPR. Studies have proved inhibitory effects of <italic>P. betel</italic> Linn. on production of allergic mediators by bone marrow derived mast cells and lung epithelial cells. PE significantly decreased histamine and granulocyte macrophage colony stimulating factors produced by an IgE mediated hypersensitive reaction and inhibited eotaxin and IL-8 secretion in a tumor necrosis factor-&#x003b1; and IL-4 induced allergic reaction.[<xref rid="ref20" ref-type="bibr">20</xref>] Reduction of oxidative stress induced by free radicals by virtue of its anti-oxidant properties and chelation of heavy metals thereby minimizing its toxic potential and increasing safety margins were also found to be reported.[<xref rid="ref21" ref-type="bibr">21</xref>] Considering all these, it is assumed that, <italic>Nagavallidala</italic> can reduce arsenic induced oxidative stress as well as the control of allergic diseases through inhibition of production of allergic mediators.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>Conclusion</title><p>The results reveal that the SPR has a significant action in cases bronchial asthma and it could suppress total leukocyte count, eosinophil count, ESR and can improve PEFR along with providing symptomatic relief. Analysis of the data generated during the study shows that; all the groups of SPR have been highly significant in treating the condition. However, comparative evaluation shows that SPRMU group is better followed by SPRT and SPRU where SPRMT is less effective comparatively. None of the treated patients developed any adverse effects during the study period.</p></sec></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agraval</surname><given-names>B</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name></person-group><article-title>A clinical trial of <italic>Moringa olieophera</italic> Lam: Clinical study</article-title><source>Indian J Pharmacol</source><year>2008</year><volume>40</volume><fpage>28</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">21264158</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caramori</surname><given-names>G</given-names></name><name><surname>Groneberg</surname><given-names>D</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Casolari</surname><given-names>P</given-names></name><name><surname>Adcock</surname><given-names>IM</given-names></name><name><surname>Papi</surname><given-names>A</given-names></name></person-group><article-title>New drugs targeting Th2 lymphocytes in asthma</article-title><source>J Occup Med Toxicol</source><year>2008</year><volume>3</volume><issue>Suppl 1</issue><fpage>S6</fpage><pub-id pub-id-type="pmid">18315837</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Jonsson</surname><given-names>B</given-names></name><name><surname>Klim</surname><given-names>JB</given-names></name></person-group><article-title>The costs of asthma</article-title><source>Eur Respir J</source><year>1996</year><volume>9</volume><fpage>636</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">8726924</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>JP</given-names></name><name><surname>Cowen</surname><given-names>P</given-names></name><name><surname>Lewis</surname><given-names>RA</given-names></name></person-group><article-title>The relationship between asthma admission rates, routes of admission, and socioeconomic deprivation</article-title><source>Eur Respir J</source><year>1996</year><volume>9</volume><fpage>2087</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">8902471</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eachus</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Grainge</surname><given-names>M</given-names></name><name><surname>Donovan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Deprivation and cause specific morbidity: Evidence from the Somerset and Avon survey of health</article-title><source>BMJ</source><year>1996</year><volume>312</volume><fpage>287</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">8611787</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Adkinson</surname><given-names>NF</given-names></name><name><surname>Bochner</surname><given-names>BS</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Lemanske</surname><given-names>RF</given-names></name><name><surname>Simons</surname><given-names>FE</given-names></name></person-group><article-title>Indoor allergens</article-title><source>Middleton's Allergy Principles and Practice</source><year>2008</year><edition>7th Ed</edition><publisher-loc>St Louis, MO</publisher-loc><publisher-name>Mosby Elsevier</publisher-name></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemery</surname><given-names>B</given-names></name><name><surname>Hoet</surname><given-names>PH</given-names></name><name><surname>Nowak</surname><given-names>D</given-names></name></person-group><article-title>Indoor swimming pools, water chlorination and respiratory health</article-title><source>Eur Respir J</source><year>2002</year><volume>19</volume><fpage>790</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12030714</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jindal</surname><given-names>SK</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name></person-group><article-title>The relationship between tobacco smoke and bronchial asthma</article-title><source>Indian J Med Res</source><year>2004</year><volume>120</volume><fpage>443</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15591628</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Takamura</surname><given-names>M</given-names></name><name><surname>Yamaoka</surname><given-names>A</given-names></name><name><surname>Odajima</surname><given-names>Y</given-names></name><name><surname>Iikura</surname><given-names>Y</given-names></name></person-group><article-title>Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood</article-title><source>Pediatr Allergy Immunol</source><year>2002</year><volume>13</volume><fpage>47</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">12000498</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Adkinson</surname><given-names>NF</given-names></name><name><surname>Bochner</surname><given-names>BS</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Lemanske</surname><given-names>RF</given-names></name><name><surname>Simons</surname><given-names>FE</given-names></name></person-group><article-title>Adverse reactions to foods: Respiratory food hypersensitivity reactions</article-title><source>Middleton's Allergy Principles and Practice</source><year>2008</year><edition>7th ed</edition><publisher-loc>St Louis, MO</publisher-loc><publisher-name>Mosby Elsevier</publisher-name></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Miller</surname><given-names>GE</given-names></name></person-group><article-title>Stress and inflammation in exacerbations of asthma</article-title><source>Brain Behav Immun</source><year>2007</year><volume>21</volume><fpage>993</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17493786</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Agivesha</surname></name><name><surname>Charaka</surname></name><name><surname>Dridhabala</surname></name></person-group><person-group person-group-type="editor"><name><surname>Vaidya Jadavaji</surname><given-names>Trikamji Acharya</given-names></name></person-group><article-title>Charaka Samhita Chikitsa Sthana, Hikkashwasa Chikitsa Adhyaya, 17/11</article-title><year>2011</year><edition>reprint edition</edition><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhambha Orientalia</publisher-name><fpage>533</fpage></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="book"><collab>Anonyms</collab><article-title>Ayurvedic Formulary of India. Part 1. Section 15/8</article-title><year>2009</year><edition>2nd revised ed</edition><publisher-loc>New Delhi</publisher-loc><publisher-name>New Delhi, Department of Health and family welfare, Department of AYUSH, Govt. of India</publisher-name><fpage>212</fpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>LF</given-names></name><name><surname>Yin</surname><given-names>KS</given-names></name></person-group><article-title>Effect of arsenic trioxide on apoptosis of pulmonary eosinophile in asthmatic guinea-pigs</article-title><source>Zhongguo Zhong Xi Yi Jie He Za Zhi</source><year>2002</year><volume>22</volume><fpage>292</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12584795</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Agivesha</surname></name><name><surname>Charaka</surname></name><name><surname>Dridhabala</surname></name></person-group><person-group person-group-type="editor"><name><surname>Vaidya Jadavaji</surname><given-names>Trikamji Acharya</given-names></name></person-group><article-title>Charaka Samhita Chikitsa Sthana, Hikkashwasa Chikitsa Adhyaya, 17/147</article-title><year>2011</year><edition>reprint edition</edition><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhambha Orientalia</publisher-name><fpage>539</fpage></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Maharaj</surname><given-names>SK</given-names></name></person-group><article-title>Rasa Tantra Sara Va Siddha Praypga Sangraha Kupipakwa Prakarana/8</article-title><year>2006</year><edition>17th ed</edition><publisher-loc>Almera</publisher-loc><publisher-name>Published by Krishna Gopal Ayurveda Bhavan</publisher-name><fpage>278</fpage></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharmila Banu</surname><given-names>G</given-names></name><name><surname>Kumar</surname><given-names>G</given-names></name><name><surname>Murugesan</surname><given-names>AG</given-names></name></person-group><article-title>Effects of leaves extract of Ocimum sanctum L. on arsenic-induced toxicity in Wistar albino rats</article-title><source>Food Chem Toxicol</source><year>2009</year><volume>47</volume><fpage>490</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19111884</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>MK</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Ocimum sanctum aqueous leaf extract provides protection against mercury induced toxicity in Swiss albino mice</article-title><source>Indian J Exp Biol</source><year>2002</year><volume>40</volume><fpage>1079</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12587743</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bhavamishra</surname></name></person-group><article-title>Bhava Prakash Nighantu-Purvardha, Pushpavarga/62-63</article-title><year>2010</year><edition>Revised</edition><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukambha Bharati Academy</publisher-name></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirotesangthong</surname><given-names>M</given-names></name><name><surname>Nagaki</surname><given-names>I</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Thanakijcharoenpath</surname><given-names>W</given-names></name><name><surname>Nagai</surname><given-names>H</given-names></name></person-group><article-title>Inhibitory effects of Piper betle on production of allergic mediators by bone marrow-derived mast cells and lung epithelial cells</article-title><source>Int Immunother</source><year>2008</year><volume>3</volume><fpage>453</fpage><lpage>7</lpage></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lean</surname><given-names>LP</given-names></name><name><surname>Mohamed</surname><given-names>S</given-names></name></person-group><article-title>Antioxidative and antimycotic effects of turmeric, lemon-grass, betel leaves, clove, black pepper leaves and <italic>Garcinia atriviridis</italic> on butter cakes</article-title><source>J Sci Food Agric</source><year>1999</year><volume>79</volume><fpage>1817</fpage><lpage>22</lpage></element-citation></ref></ref-list></back></article>